期刊文献+

毛细管区带电泳测定唑来膦酸及其制剂的含量 被引量:1

Determination of zoledronic acid and its preparations by capillary zone electrophoresis
下载PDF
导出
摘要 目的:建立简便、快速分析唑来膦酸及与其有关物质的毛细管区带电泳方法。方法:采用非涂渍石英毛细管(50cm×50 μm)为分离通道,3 mmol·L^(-1)磷酸盐缓冲液(pH 7.9)为运行缓冲体系;工作电压25 kV;进样电压2 kV,进样时间5 s;紫外检测波长为210nm。结果:唑来膦酸在31.2~998μg·mL^(-1)的范围内线性关系良好(r=0.9997);注射用唑来膦酸的平均回收率(n=9)为100.2%,RSD 为1.1%;唑来膦酸注射剂的平均回收率(n=9)为100.7%,RSD 为1.0%;最低检测限为10.4μg·mL^(-1),该条件下唑来膦酸与其有关物质分离良好。结论:本方法简便、快速、灵敏,为唑来膦酸生产合成中的质量控制提供了一种新的可靠的分析手段。 Objective:To estebalish a simple and rapid capillary zone electrophoresis method for the analysis of zoledronic acid and its related substance. Methods :An uncoated fused - silica capillary column of 50 cm×50 μm was used. The method was developed by utilizing a eleetrokinetic injection(2 kV,5 s) , a running voltage of 25 kV and a 3 mmol·L^-1 phosphate electrolyte solution at pH 7.9. The detection wavelength was 210 nm. Results:The calibration curve was linear in the range of 31.2 -998μg ·mL^-3(r =0. 9997) ,the average recovery of zoledronie acid for injection was 100.2% with RSD of 1.1% ;for zoledronic acid injection the average recovery was 100.7% with RSD of 1.0% ;the LOD was 10. 4μg·mL^-1 ,the active ingredient - zoledronic acid was successfully separated from its related substance. Conclusion: The method is simple, rapid and accurate ; it provides a new reliable means for the quality control of zoledronic acid.
出处 《药物分析杂志》 CAS CSCD 北大核心 2008年第6期870-872,共3页 Chinese Journal of Pharmaceutical Analysis
基金 河北省自然科学基金资助项目(C2004000562)
关键词 毛细管区带电泳 唑来膦酸 含量测定 有关物质 capillary zone electrophoresis zoledronic acid content determination related substance
  • 相关文献

参考文献8

二级参考文献14

  • 1[2]Cheer SM,Noble S.Zoledronic Acid[J].Drugs,2001,61(6):799-805.
  • 2中华人民共和国药典委员会.中华人民共和国药典[S]2000年版[M].北京:化学工业出版社,2000..
  • 3Skerjanel A, Berenson J, Hsu C, et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function[J].J Clin Pharmacol,2003,43(2) : 154.
  • 4Chen T, Berenson J. Vescio R, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patienls with bone metastases[J].J Clin Pharmacol. 2002.42(11):1228.
  • 5The Board of Trustees The United States Pharmacopoeia 26& the National Formulary 19 [S].Rockville:The United States PharmacopeialConvention,2003.767 768
  • 6Francois L, Sonia G, Fabienne D, et al. Development and valida tion of a highly sensitive RIA for zoledronic acid, a new potent heterocyclic bisphosphonate, in human serum, plasma and urine[ J ]. J Pharm Biomed Anal ,2002,30(Suppl 4) :S897 - S911.
  • 7Forsman U, Andersson M, Tornros H. Ion-exchange chromatography with post-column reaction for the analysis of phosphonoformance, phosphate and phosphate[ J ]. J Chromatogr, 1986,369 (1):151- 157.
  • 8Takashi U,Takashi W,Saburo H. Determination of a new dispho sphonate, YM175, in plasma, urine and bone by high -performance liquid chromatography with electrochemical detection[J ]. J Chromatogr, 1992,584(2): 213 - 220.
  • 9Susan M Cheer,Stuart NobLe.ZoLedronic Acid[J].Drugs, 2001, 61(6): 799.
  • 10方洪壮,孙长海.依替膦酸钠的电位滴定[J].中国医药工业杂志,1998,29(4):174-176. 被引量:13

共引文献11

同被引文献5

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部